Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 550

1.

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL.

J Clin Oncol. 2019 Oct 14:JCO1901389. doi: 10.1200/JCO.19.01389. [Epub ahead of print]

PMID:
31609651
2.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M.

Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9. [Epub ahead of print] No abstract available.

PMID:
31558766
3.

Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.

Nanni L, Pellegrini C, Stefoni V, Argnani L, Cavo M, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Aug 30. pii: S2152-2650(19)31251-0. doi: 10.1016/j.clml.2019.07.443. [Epub ahead of print] No abstract available.

PMID:
31543370
4.

Are Biosimilars the Future of Oncology and Haematology?

Zinzani PL, Dreyling M, Gradishar W, Andre M, Esteva FJ, Boulos S, González Barca E, Curigliano G.

Drugs. 2019 Oct;79(15):1609-1624. doi: 10.1007/s40265-019-01193-y.

PMID:
31541401
5.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2019 Sep 20. pii: mdz386. doi: 10.1093/annonc/mdz386. [Epub ahead of print] No abstract available.

PMID:
31539020
6.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH.

Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13.

PMID:
31409671
7.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492. [Epub ahead of print]

PMID:
31398081
8.

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia.

Broccoli A, Bertuzzi C, Fiorentino M, Morigi A, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL.

Onco Targets Ther. 2019 Jun 20;12:4807-4812. doi: 10.2147/OTT.S202061. eCollection 2019.

9.

Spontaneous remission of follicular lymphoma.

Morigi A, Casadei B, Argnani L, Cavo M, Zinzani PL.

Hematol Oncol. 2019 Jul 23. doi: 10.1002/hon.2653. [Epub ahead of print]

PMID:
31334854
10.

Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.

Zanoni L, Broccoli A, Lambertini A, Pellegrini C, Stefoni V, Lodi F, Fonti C, Nanni C, Zinzani PL, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1661-1671. doi: 10.1007/s00259-019-04323-6. Epub 2019 May 17.

PMID:
31102000
11.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Nowakowski GS, Feldman T, Rimsza LM, Westin JR, Witzig TE, Zinzani PL.

Blood Cancer J. 2019 May 16;9(6):48. doi: 10.1038/s41408-019-0208-6. Review.

12.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
13.

Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.

Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F, Tura S, Barosi G.

Leuk Res. 2019 Jun;81:88-94. doi: 10.1016/j.leukres.2019.04.016. Epub 2019 May 2. Review.

PMID:
31055248
14.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.

von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Zinzani PL, Giezek H, Balakumaran A, Vo TT, Raut M, Brice P.

Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262. [Epub ahead of print]

PMID:
31012356
15.

Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.

Jurczak W, M Gruszka A, Sowa Staszczak A, Dlugosz-Danecka M, Szostek M, Zimowska-Curylo D, Giza A, Krawczyk K, Jakobczyk M, Hubalewska-Dydejczyk A, Szymczyk M, Wróbel T, Knopińska-Posłuszny W, Kisiel E, Skotnicki A, Zinzani PL.

Leuk Lymphoma. 2019 Apr 9:1-8. doi: 10.1080/10428194.2019.1602261. [Epub ahead of print]

PMID:
30961415
16.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

PMID:
30940746
17.

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J.

Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.

PMID:
30935953
18.

Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma.

Eskian M, Khorasanizadeh M, Zinzani PL, Illidge TM, Rezaei N.

Int Rev Immunol. 2019;38(2):79-91. doi: 10.1080/08830185.2019.1588266. Epub 2019 Mar 31.

PMID:
30931651
19.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators.

J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.

20.

PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.

Casadei B, Broccoli A, Stefoni V, Pellegrini C, Marangon M, Morigi A, Nanni L, Lolli G, Carella M, Argnani L, Cavo M, Zinzani PL.

Haematologica. 2019 Mar 19. pii: haematol.2019.215962. doi: 10.3324/haematol.2019.215962. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center